Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

, CRM

Salesforce

$74.10

3.19 (4.50%)

09:55
10/10/16
10/10
09:55
10/10/16
09:55

Early notable gainers among liquid option names on October 10th

Notable gainers among liquid option names this morning include Mylan (MYL) $39.27 +3.34, Salesforce.com (CRM) $75.18 +4.29, Tyson (TSN) $70.37 +2.62, Murphy (MUR) $30.41 +0.91, and Transocean (RIG) $10.41 +0.29.

MYL

Mylan

$35.94

-0.9 (-2.44%)

CRM

Salesforce

$74.10

3.19 (4.50%)

TSN

Tyson Foods

$70.37

2.62 (3.87%)

MUR

Murphy Oil

$30.47

0.96 (3.25%)

RIG

Transocean

$10.47

0.345 (3.41%)

  • 27

    Oct

  • 09

    Nov

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
UBSW
10/10/16
NO CHANGE
Target $60
UBSW
Buy
UBS remains constructive on Mylan despite governance controversy
UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman cited the company's ability to execute, its surprise announcement of a EpiPen Medicaid lawsuit settlement and its updated guidance, which was better than feared. Goodman reiterated his Buy rating and lowered his price target to $60 from $66 on Mylan shares.
CRM Salesforce
$74.10

3.19 (4.50%)

10/10/16
JPMS
10/10/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees 'opportune entry point' for Salesforce
JPMorgan analyst Mark Murphy believes shares of Salesforce (CRM) are at an "'opportune entry point" following the recent selloff. The pullback has been driven by a "slightly soft" Q2 and concerns about a potentially expensive acquisition of Twitter (TWTR), Murphy tells investors in a research note. After speaking to industry contacts at Dreamforce, the analyst sees a path for the "overhangs to fade" with a "better pace of business in Q3/Q4" as well as the eventual fading of the Twitter discussion. Murphy reiterates an Overweight rating on Salesforce with a $95 price target in a research note titled "The Most Valuable Cloud Asset Is Undeservedly Undervalued."
10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
TSN Tyson Foods
$70.37

2.62 (3.87%)

10/07/16
JEFF
10/07/16
NO CHANGE
JEFF
Follow-up: Tyson Foods price fixing allegations 'unfounded,' says Jefferies
Jefferies analyst Akshay Jagdale believes weakness in Tyson shares due to price fixing allegations is overdone. The analyst sees no evidence of consumers being harmed by price fixing and believes chicken prices and the industry is highly competitive and consumers have benefited from this. His analysis of the industry indicates historical chicken price movements can be explained by fundamentals and price discovery is relatively transparent.
10/07/16
JEFF
10/07/16
NO CHANGE
JEFF
Tyson Foods price fixing allegations 'unfounded,' says Jefferies
10/10/16
LYON
10/10/16
UPGRADE
LYON
Buy
Tyson Foods upgraded to Buy from Outperform at CLSA
CLSA analyst Jeremy Scott upgraded Tyson Foods to Buy and increased its price target to $86 from $85 saying the class action suit is baseless and lacks any victims. Scott said the case is flawed because it lacks evidence, misrepresents the consequences, badly confuses game theory with collusion. He notes the wholesale broiler composite has averaged 70c/lb over the past 12 months, down 1% from the 2008 level of 71s, compared to beef, up 40% and pork up 20%. Scott recommends investors take advantage of the unsubstantiated noise and buy shares.
10/10/16
JPMS
10/10/16
NO CHANGE
JPMS
Neutral
Tyson Foods selloff Friday a buying opportunity, says JPMorgan
JPMorgan analyst Ken Goldman recommends using Friday's weakness in shares of Tyson Foods as a buying opportunity. The complaint filed against chicken producers last month appears to have insufficient evidence at this time, Goldman tells investors in a research note. He expects Tyson to report "very strong" results over the next "quarter or two" and keeps the Neutral-rated shares on his firm's Focus List.
MUR Murphy Oil
$30.47

0.96 (3.25%)

06/20/16
06/20/16
UPGRADE

Market Perform
Murphy Oil upgraded to Market Perform, dividend safe, says Raymond James
As previously reported, Raymond James upgraded Murphy Oil to Market Perform from Underperform. Analyst Pavel Molchanov believes Murphy's dividend is safe in conjunction with an increase today in the firm's 2017 oil price forecast.
06/20/16
06/20/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA) upgraded to Buy from Neutral at Buckingham with the firm's analyst viewing risk/reward as favorable and expects pricing will stabilize in Q4, driving margin improvement and setting up Under Armour for 2017 earnings upside when it also begins to materially expand distribution. 2. Yelp (YELP) upgraded to Buy from Hold at Deutsche Bank with analyst Lloyd Walmsley saying the company is likely to exceed 2016 guidance and consensus estimates. The analyst raised his price target for the shares to $33 from $26 citing stabilized sales force productivity, more confidence in management and improvements in ad units. 3. Expedia (EXPE) upgraded to Overweight from Neutral at Atlantic Equities with analyst James Cordwell expecting material earnings growth from Expedia's non-core OTA assets, HomeAway, Orbitz, trivago. Even with conservative outlook for the core OTA business, Cordwell believes the diversification should also aid the stock's multiple. 4. Murphy Oil (MUR) upgraded to Market Perform from Underperform at Raymond James with analyst Pavel Molchanov believing Murphy's dividend is safe in conjunction with an increase today in the firm's 2017 oil price forecast. 5. Symantec (SYMC) upgraded to Buy from Sell at UBS with analyst Brent Thill double upgrading the stock arguing that the acquisition of Blue Coat Systems, while "not a silver bullet" for either party, will drive favorable near-term financials. Thill raised his price target for the shares to $24 from $16. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/13/16
LEHM
07/13/16
UPGRADE
Target $42
LEHM
Overweight
Murphy Oil upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Paul Cheng upgraded Murphy Oil to Overweight after raising his Americas Integrated Oil sector view to Positive. The global oil market is currently in the "midst of a continued upward trajectory" in which Brent could average $85 by Q4 of 2017 and $80-$90 between 2018 and 2021, Cheng tells investors in a research note. He believes the risks associated with Murphy Oil have been priced into the shares at current levels. The analyst upped his price target for the stock to $42 from $33.
07/13/16
07/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pandora (P) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stan Meyers saying the company is nearing an inflection point and that "meaningful upside" lies ahead. 2. Murphy Oil (MUR) upgraded to Overweight from Equal Weight at Barclays with analyst Paul Cheng saying the global oil market is currently in the "midst of a continued upward trajectory" in which Brent could average $85 by the fourth quarter of 2017 and $80-$90 between 2018 and 2021. 3. NuVasive (NUVA) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Hanover saying the company's first quarter outperformance "was not a fluke." 4. PSEG (PEG) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Stephen Byrd saying he expects stronger post-2017 earnings power based on the company's significant pipeline of regulated investment opportunities and the upcoming rate case to be filed in 2017. 5. Wright Medical (WMGI) upgraded to Overweight from Neutral at JPMorgan with analyst Andrew Hanover saying Wright over the past year has transformed into the only publicly traded orthopedics company with a revenue base of over $500M and a projected top-line growth rate north of 10%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RIG Transocean
$10.47

0.345 (3.41%)

09/19/16
SUSQ
09/19/16
NO CHANGE
SUSQ
Susquehanna lowers price targets on several offshore drillers
Susquehanna analyst Charles Minervino lowered his estimates and price targets on offshore drillers by an average of 17%, citing lower crude prices, extended softness in new contracting activity, and expectations for a prolonged period of low dayrates. Minervino lowered his price target on Neutral rated companies Atwood Oceanics (ATW) to $7 from $11, Diamond Offshore (DO) to $16 from $18, Ensco (ESV) to $7 from $8, Noble Corp. (NE) to $5 from $6, Rowan (RDC) to $12 from $14, and Transocean (RIG) to $10 from $11.
09/23/16
FBCO
09/23/16
UPGRADE
FBCO
Neutral
Transocean upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Gregory Lewis is upgraded Transocean to Neutral and raised its price target to $8 from $5. Lewis said management has been extending Transocean's duration and expects the company's diverse foot print and relationships to drive increased contracts.
10/04/16
HOWW
10/04/16
UPGRADE
Target $14
HOWW
Outperform
Transocean upgraded to Outperform from Sector Perform at Scotia Howard Weil
Scotia Howard Weil analyst Blake Hancock upgraded Transocean to Outperform and raised its price target to $14 from $12.
09/15/16
09/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Hold from Sell at Canaccord with analyst Alex Brooks citing valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from Perform at Oppenheimer analyst Brian Nagel citing the potential for better near-term sales trends as "weaker players" in sporting goods retail fail. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying volume trends across the company's commercial portfolio suggests the base business is "on sustainable footing." 4. Petrobras (PBR) upgraded to Neutral from Underperform at Macquarie with analyst Giacomo Romeo saying near-term liquidity is less concerning after recent divestitures, an improved political outlook, and the re-gained access to the bond market. 5. bluebird bio (BLUE) upgraded to Conviction Buy from Buy at Goldman with analyst Salveen Richter saying he expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

PVTB

PrivateBancorp

$48.78

2 (4.28%)

, CM

CIBC

$81.64

0.26 (0.32%)

14:41
12/02/16
12/02
14:41
12/02/16
14:41
Hot Stocks
Alpine Associates opposes PrivateBancorp's acquisition by CIBC »

Alpine Associates…

PVTB

PrivateBancorp

$48.78

2 (4.28%)

CM

CIBC

$81.64

0.26 (0.32%)

KRE

SPDR S&P Regional Banking ETF

$53.05

-0.415 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMX

BioPharmX

$0.38

0.0729 (23.52%)

14:38
12/02/16
12/02
14:38
12/02/16
14:38
Hot Stocks
Breaking Hot Stocks news story on BioPharmX »

Vivo Capital VIII reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$118.87

0.36 (0.30%)

14:37
12/02/16
12/02
14:37
12/02/16
14:37
Hot Stocks
Celgene agrees to complete acquisition of Acetylon »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

  • 06

    Dec

KVHI

KVH Industries

$10.85

-0.05 (-0.46%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Hot Stocks
KVH Industries names Donald Reilly CFO »

KVH Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$109.28

-2.37 (-2.12%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Options
GW Pharmaceuticals put volume heavy and directionally bearish »

Bearish flow noted in GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

, RUT

Russell 2000 Index

14:23
12/02/16
12/02
14:23
12/02/16
14:23
Technical Analysis
On The Fly: Weekly technical notes for the Russell 2000 »

The index at time of…

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$189.72

-1.76 (-0.92%)

14:21
12/02/16
12/02
14:21
12/02/16
14:21
Recommendations
Mohawk analyst commentary  »

Mohawk a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.20

0.32 (2.48%)

14:15
12/02/16
12/02
14:15
12/02/16
14:15
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

14:15
12/02/16
12/02
14:15
12/02/16
14:15
General news
Fedspeak will be compressed next week »

Fedspeak will be…

EDU

New Oriental Education

$47.96

-1.03 (-2.10%)

14:08
12/02/16
12/02
14:08
12/02/16
14:08
Periodicals
New Oriental Education engaged in college application fraud, Reuters says »

Former and current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

, SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

14:07
12/02/16
12/02
14:07
12/02/16
14:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
12/02/16
12/02
14:05
12/02/16
14:05
General news
Oil rallies while equities stall »

Stocks have stalled out,…

TITN

Titan Machinery

14:02
12/02/16
12/02
14:02
12/02/16
14:02
Downgrade
Titan Machinery rating change  »

Titan Machinery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

, BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

14:01
12/02/16
12/02
14:01
12/02/16
14:01
Hot Stocks
Sonoco to invest $20M in new Atlanta packaging center to support Duracell ops »

Sonoco (SON) announced it…

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

BRK.B

Berkshire Hathaway

$159.07

-1.05 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 02

    Dec

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Hot Stocks
Breaking Hot Stocks news story on New Oriental Education »

New Oriental down over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Periodicals
Breaking Periodicals news story on New Oriental Education »

Standards council to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYCC

ClubCorp

$13.40

0.2 (1.52%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Options
Call buyer opens the largest open interest block in ClubCorp options »

Call buyer opens the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
12/02/16
12/02
14:00
12/02/16
14:00
General news
NY Fed accepted $167.88 B in daily reverse repos »

NY Fed accepted $167.88 B…

SBUX

Starbucks

$58.51

0.54 (0.93%)

13:51
12/02/16
12/02
13:51
12/02/16
13:51
Hot Stocks
Starbucks in 'capable hands' after 'surprising' CEO change, analysts say »

Shares of Starbucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TOT

Total

$47.82

0.07 (0.15%)

, RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

13:50
12/02/16
12/02
13:50
12/02/16
13:50
Periodicals
Obama expected to sign bill extending Iran sanctions, Reuters reports »

White House says…

TOT

Total

$47.82

0.07 (0.15%)

RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

BP

BP

$35.56

0.17 (0.48%)

XOM

Exxon Mobil

$87.36

0.12 (0.14%)

CVX

Chevron

$113.34

0.05 (0.04%)

COP

ConocoPhillips

$48.17

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 13

    Dec

SDRL

Seadrill

$2.93

-0.15 (-4.87%)

13:50
12/02/16
12/02
13:50
12/02/16
13:50
Options
Far downside puts opened in Seadrill »

Far downside puts opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/02/16
12/02
13:50
12/02/16
13:50
General news
Action Economics Survey results: »

Action Economics Survey…

13:43
12/02/16
12/02
13:43
12/02/16
13:43
Conference/Events
JPMorgan aerospace & defense analyst holds an analyst/industry conference call »

Aerospace & Defense…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.